Show simple item record

dc.contributor.authorKitchener, HC
dc.contributor.authorGilham, C
dc.contributor.authorSargent, A
dc.contributor.authorBailey, A
dc.contributor.authorAlbrow, R
dc.contributor.authorRoberts, C
dc.contributor.authorDesai, M
dc.contributor.authorMather, J
dc.contributor.authorTurner, A
dc.contributor.authorMoss, S
dc.contributor.authorPeto, J
dc.date.accessioned2018-08-14T14:46:42Z
dc.date.issued2011-04
dc.identifier6
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, 2011, 47 pp. 864 - 871
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2335
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2011.01.008
dc.description.abstractBackground: The additional sensitivity of HPV testing compared with cytology could permit extended cervical screening intervals. We wished to determine, through a further (third) round of screening in the ARTISTIC trial, the protection provided by a negative baseline HPV screen compared with that of cytology over a 6 year period. Methods: Cumulative rates of CIN2 or worse (CIN2+) and CIN3 or worse (CIN3+) were correlated with baseline HPV status and cytology. HPV was detected using the Hybrid Capture 2 (Qiagen) assay for high risk types and genotyped using the Linear Array (Roche) and Papillocheck (Greiner) assays. LBC was performed using ThinPrep (Hologic). Findings: Round 3 included 8,873 women of whom 6,337 had been screened in both rounds 1 and 2 and 2,536 had not been screened since round 1. The median duration of follow-up was 72.7 months. The cumulative rate of CIN2+ over three rounds was 3.88% (95%CI 3.59%, 4.17%) overall; 2.39% in round 1, 0.78% in round 2 and 0.74% in round 3. Cumulative rates by baseline status were 20.53% (95%CI 19.04%, 22.08%) for abnormal cytology, 20.12% (95%CI 18.68%, 21.61%) for HPV detection, 1.41% (95%CI 1.19%, 1.65%) for negative cytology and 0.87% (95%CI 0.70%, 1.06%) for a negative HPV test. In HPV negative women aged over 50 the cumulative rate was 0.16% (95%CI 0.07%, 0.34%). Women who were HPV positive/cytology negative at entry had a cumulative CIN2+ rate of 7.73% (95%CI 6.29%, 9.36%) over 6 years, twice the overall rate. Interpretation: A negative HPV test was significantly more protective than normal cytology over three rounds. The findings of this extension of ARTISTIC suggest that the screening interval could be extended to 6 years if HPV testing replaced cytology as the primary screening test. (C) 2011 Elsevier Ltd. All rights reserved.
dc.format.extent864 - 871
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.titleA comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.ejca.2011.01.008
rioxxterms.licenseref.startdate2011-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEUROPEAN JOURNAL OF CANCER
pubs.notesaffiliation: Kitchener, HC (Reprint Author), Univ Manchester, Sch Canc & Enabling Sci, Manchester Acad Hlth Sci Ctr, St Marys Hosp, Res Floor,5th Floor,Oxford Rd, Manchester M13 9WL, Lancs, England. Kitchener, Henry C.; Albrow, Rebecca, Univ Manchester, Sch Canc & Enabling Sci, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England. Gilham, Clare; Peto, Julian, London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1, England. Sargent, Alexandra; Bailey, Andrew; Turner, Andrew, Cent Manchester Univ Hosp NHS Fdn, Dept Virol, Manchester, Lancs, England. Roberts, Christopher, Univ Manchester, Sch Community Based Med, Manchester Acad Hlth Sci Ctr, Hlth Sci Res Grp, Manchester M13 9WL, Lancs, England. Desai, Mina; Mather, Jean, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Cytol Ctr, Manchester, Lancs, England. Moss, Sue, Inst Canc Res, Canc Screening Evaluat Unit, Sutton, Surrey, England. keywords: Cervical; Screening; HPV; DNA testing keywords-plus: HUMAN-PAPILLOMAVIRUS 16/18; INTRAEPITHELIAL NEOPLASIA; CANCER; WOMEN; UK; ABNORMALITIES; IMPACT research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] funding-acknowledgement: NIHR [98/04/99]; NIHR Manchester Biomedical Research Centre; National Institute for Health Research [98/04/99, 98/04/64] funding-text: This project was funded by the NIHR Health Technology Assessment Programme (Project number 98/04/99) and will be published in full in the Health Technology Assessment journal, 2011. See the HTA programme website for further project information.; This work was supported by the NIHR Manchester Biomedical Research Centre. number-of-cited-references: 16 times-cited: 80 usage-count-last-180-days: 0 usage-count-since-2013: 5 journal-iso: Eur. J. Cancer doc-delivery-number: 757AP unique-id: ISI:000290056500008 da: 2018-08-14
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.volume47
pubs.embargo.termsNot known
icr.researchteamCancer Screening Evaluation Unit (DoH)en_US
dc.contributor.icrauthorMoss, Susan Maryen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record